iPSirius is creating a new frontier in stem cell-based cancer therapeutics by developing a vaccine to fight aggressive tumors.
Paris, France, 19th December 2022 – iPSirius is a European immunotherapy company that is working to bring a new range of off-the-shelf vaccines to cancer patients worldwide to improve their prognosis and quality of life. iPSirius has developed a pipeline of engineered induced pluripotent stem cell (iPS) vaccines using its proprietary iPVAC technology.
Pivotal to the company bringing these new cancer vaccines to the clinic is the innovative technology that won a very competitive Pathfinder Award from the European Innovation Council. This secured $2M to translate the technology to the clinic. The European Innovation Council gives out the EIC Pathfinder award to “support research teams to develop emerging breakthrough technologies”.
“We are very grateful to European Innovation Council for this necessary financial support that will accelerate access of our stem cell vaccine pipeline to the clinic. Our team at iPSirius is eager to develop off-the-shelf, cell-based vaccines that can improve the quality of life for patients with aggressive cancers worldwide. We hope that these new cancer vaccines will be transformative to the field of cancer therapy,” said co-Founder and Chief Medical Officer, Prof Ali Turhan.
iPSirius is addressing key challenges in treating non-immunogenic solid tumors, based on the immunogenic properties of stem cells.
More details can be found at the company website, www.iPSirius.com.